生存素与CD34在急性髓系白血病患者骨髓细胞中的表达

摘要

Objective To investigate the relationship of bone marrow cell expression of snrvivin and cluster of differentiation 34 ( CD34 ) in the development of acute myeloid leukemia ( AML ). Methods The snrvivin and CD34 were detected by flow cytometry in 62 patients with AML and 31 patients with non-malignant hematopathy. Results The percentage of the expression of snrvivin+ /CD34 + in bone marrow cells of patients with AML [ ( 13. 74 ± 10. 92 )% ] was obviously higher than that of control group [ ( 2. 53 ± 1. 85 )% , P < 0. 01 ], and that of remission group [(4.01 ± 1.41 )% ] was lower than that of non-remission group[ ( 23. 83 ± 20. 42 )% , P < 0. 01 ]. The percentage of the expression of snrvivin + /CD34- in bone marrow cells of patients with AML [ ( 22. 07 ± 16. 95 )% ] was obviously higher than that of control group [( 12.29 ±8.80 )%, P<0.05 ], and that of remission group [( 14.32 ±7.53 )% ] was lower than that of non-remission group [ ( 29. 83 ±26. 37 )% , P <0. 05 ]. Conclusions In the detection of hematopathy, the expression of snrvivin in bone marrow cells has the role of outcome with screening. The expression of snrvivin has closer relationship with the development of leukemia than CD34, and has a certain significance in the treatment and prognosis assessment of AML.%目的 探讨骨髓细胞中生存素(survivin)和白细胞分化抗原34(CD34)的表达与急性髓系白血病(AML)发生、发展的关系.方法 采用流式细胞术检测62例AML患者和31例非恶性血液病患者骨髓细胞中的survivin及CD34.结果 survivin+/CD34+双表达:AML组骨髓细胞的survivin+/CD34+双表达为(13.74±10.92)%,明显高于对照组(2.53±1.85)%(P<0.01),且治疗缓解组[(4.01±1.41)%]低于治疗未缓解组[(23.83±20.42)%](P<0.01).survivin+/CD34-表达:AML组骨髓细胞的survivin+/CD34-表达为(22.07±16.95)%,明显高于对照组[(12.29±8.80)%](P<0.05),且治疗缓解组[(14.32±7.53)%]低于治疗未缓解组[(29.83±26.37)%](P<0.05).结论 骨髓细胞中survivin表达的检测对血液疾病的转归具有提示的作用,且比CD34和白血病发生、发展的关系更加密切;对AML的治疗效果及预后有一定的评估价值.